ERBB2 and gastric cancer: The biomarkers recommended in the current clinical practice guideline include human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI) status, and programmed death ligand 1 (PD-L1) [6] These biomarkers are focused on predicting drug response in patients with advanced gastric cancer who receive chemotherapy.